

(19)



(11)

EP 3 710 485 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:

C07K 16/28 ^(2006.01) **A61K 47/68** ^(2017.01)

(48) Corrigendum issued on:

23.06.2021 Bulletin 2021/25

(86) International application number:

PCT/US2019/034701

(45) Date of publication and mention of the grant of the patent:

31.03.2021 Bulletin 2021/13

(87) International publication number:

WO 2019/232241 (05.12.2019 Gazette 2019/49)

(21) Application number: **19732174.8**

(22) Date of filing: **30.05.2019**

(54) **ANTI-SEZ6 ANTIBODY DRUG CONJUGATES AND METHODS OF USE**

ANTI-SEZ6-ANTIKÖRPER-ARZNEIMITTELKONJUGATE UND DEREN
 VERWENDUNGSMETHODEN

CONJUGUES DES ANTICORPS ANTI-SEZ6 ET LEURS PROCEDES D'UTILISATION

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
 GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
 PL PT RO RS SE SI SK SM TR**

Designated Extension States:

**BA ME
 KH MA MD TN**

- **GAVRILYUK, Julia**
San Diego, CA 92130 (US)
- **SCHAMMEL, Alexander**
San Francisco, California 94114 (US)

(30) Priority: **30.05.2018 US 201862678061 P**

(74) Representative: **J A Kemp LLP**

**14 South Square
 Gray's Inn
 London WC1R 5JJ (GB)**

(43) Date of publication of application:

23.09.2020 Bulletin 2020/39

(56) References cited:

**WO-A1-2013/126810 WO-A1-2015/031698
 WO-A1-2016/141285 WO-A1-2016/172273
 WO-A1-2017/112803 WO-A2-03/092623
 WO-A2-2005/089808**

(60) Divisional application:

21157876.0

(73) Proprietor: **AbbVie Stemcentrx LLC**

North Chicago, IL 60064-6400 (US)

- **JAIN NARESHKUMAR ET AL: "Current ADC Linker Chemistry", PHARMACEUTICAL RESEARCH, SPRINGER NEWYORK LLC, US, vol. 32, no. 11, 11 March 2015 (2015-03-11), pages 3526-3540, XP035553874, ISSN: 0724-8741, DOI: 10.1007/S11095-015-1657-7 [retrieved on 2015-03-11]**

(72) Inventors:

- **LIU, David**
Pacifica, California 94044 (US)

EP 3 710 485 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).